Search

Displaying results 541 - 550 of 3599 in total
  1. Drug

    Denosumab

    go.drugbank.com/drugs/DB06643
    ApprovedInvestigational

    It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss. … Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of

  2. Drug

    Pesampator

    go.drugbank.com/drugs/DB11843
    Investigational

    PF-04958242 has been used in trials studying the basic science and treatment of Schizophrenia and Hearing Loss, Sensorineural.

  3. Drug

    Scopolamine

    go.drugbank.com/drugs/DB00747
    ApprovedInvestigational

    Scopolamine is a tropane alkaloid isolated from members of the Solanaceae family of plants, similar to atropine and hyoscyamine, all of which structurally mimic the natural neurotransmitter acetylcholine. Scopolamine was first synthesize...

    Mixtures: PB Hyos, Re-PB HyosCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  4. Drug

    Idelalisib

    go.drugbank.com/drugs/DB09054
    ApprovedInvestigational

    More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. … The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  5. Drug

    Monobenzone

    go.drugbank.com/drugs/DB00600
    ApprovedWithdrawn

    Monobenzone is the monobenzyl ether of hydroquinone used medically for depigmentation. Monobenzone occurs as a white, almost tasteless crystalline powder, soluble in alcohol and practically insoluble in water. It exerts a depigmenting ef...

    Synonyms: p-(Benzyloxy)phenol, Benzyl p-hydroxyphenyl ether
  6. Drug

    Temozolomide

    go.drugbank.com/drugs/DB00853
    ApprovedInvestigational

    [A229848, A229858, L32033] Temozolomide is an imidazotetrazine prodrug that is stable at acidic pH but undergoes spontaneous nonenzymatic hydrolysis at neutral or slightly basic pH; these properties allow

    Categories: P-glycoprotein substrates, P-glycoprotein substrates with a Narrow Therapeutic Index
  7. Drug

    Phendimetrazine

    go.drugbank.com/drugs/DB01579
    ApprovedIllicit

    Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970.

    Categories: Adrenergic alpha-1 Receptor Agonists
  8. Drug

    Maridebart Cafraglutide

    go.drugbank.com/drugs/DB19339
    Investigational

    Maridebart Cafraglutide is under investigation in clinical trial NCT05669599 (Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes ...

    Synonyms: Immunoglobulin G1, anti-(glucose-dependent insulinotropic polypeptide receptor) [275-cysteine,295-cysteine,300-glycine,305-cysteine] (human γ1-chain), disulfide with human κ-chain, dimer, 275,275′-bis(
  9. Drug

    Bretylium

    go.drugbank.com/drugs/DB01158
    Approved

    Recent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site.

  10. Drug

    Selumetinib

    go.drugbank.com/drugs/DB11689
    ApprovedInvestigational

    The novel MEK 1/2 inhibitor, selumetinib, was initially approved solely for the treatment of pediatric patients with Neurofibromatosis type 1 (NF-1) and symptomatic, inoperable plexiform neurofibromas (PN

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates